四联活菌肠溶胶囊治疗慢性腹泻的疗效评价

目的探讨四联活菌肠溶胶囊（双歧杆菌、乳杆菌、肠球菌、芽孢杆菌）治疗慢性腹泻的临床疗效及安全性。方法将284例慢性腹泻患者随机分为两组,其中观察组142例接受四联活菌肠溶胶囊治疗;对照组142例接受双歧三联活菌肠溶胶囊（长型双歧杆菌、嗜酸乳杆菌、粪肠球菌）治疗。所有患者的疗程均为14d。结果 （1）观察组患者的治疗效果显著优于对照组,两组患者之间治疗效果的比较差异有统计学意义（P〈0.05）。（2）观察组与对照组不良反应发生率分别为9.9%（14/142）、8.5%（12/142）,两组患者的不良反应发生率相比差异无统计学意义（P〉0.05）。结论四联活菌肠溶胶囊治疗慢性腹泻的疗效确切,是治疗慢性腹泻的理想手段。

Evaluation of therapeutic efficacy of tetravaccine enteric-coated capsules in the treatment of chronic diarrhea

Objective To explore the clinical efficacy and safety of tetravaccine enteric-coated capsules （bifidobacterium, lactobacillus, enterococcus, bacillus） in the treatment of chronic diarrhea. Methods Two hundred and eighty-four cases of chronic diarrhea were divided into two groups, and the observation group （n=142） was received tetravaccine enteric-coated capsules, while the control group （n=142） was given probiotics enteric-coated capsules （long bifidobacterium, lactobacillus acidophilus, enterococcus faecalis）. All patients were treated for 14 days. Results （1）The therapeutic efficacy of observation group was significantly better than that of control group （P 0.05）. （2）The incidence rate of adverse reactions of observation group and control group was 9.9% （14/142） and 8.5%（12/142）, and there was no significant difference in the incidence rate of adverse reactions between the two groups （P 0.05）. Conclusion The tetravaccine enteric-coated capsules in the treatment of chronic diarrhea shows good therapeutic efficacy, and this treatment program is an ideal method for chronic diarrhea.